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S U M M A R Y
Objective: The aim of this study was to determine whether N-terminal pro-B-type natriuretic peptide
(NT-proBNP) can predict impending brainstem encephalitis, pulmonary edema, pulmonary hemorrhage,
cardiopulmonary failure, and death in children with severe enterovirus 71 (EV71)-associated hand, foot,
and mouth disease (HFMD).
Methods: Plasma NT-proBNP levels of 282 children with severe EV71-associated HFMD were measured.
Results: NT-proBNP levelswere signiﬁcantly higher in patientswith elevated blood glucose (>7.8mmol/l)
and increased white blood cell counts (>14  109/l). HFMD patients who had no complications had
signiﬁcantly lower NT-proBNP values than patients who died or had complications (p< 0.05). The area
under the receiver operating characteristic (ROC) curvewas 0.73, 0.87, 0.91, 0.93, and 0.92 to discriminate
between patients with and without brainstem encephalitis, pulmonary edema, pulmonary hemorrhage,
circulatory failure, and death, respectively, using NT-proBNP. An NT-proBNP cut-off value of1300 pg/ml
demonstrated a high sensitivity (85.00%) and speciﬁcity (93.51%) for predicting death in critical HFMD
patients. Children with severe EV71-associated HFMD and NT-proBNP measurements 1300 pg/ml had
signiﬁcantly worse overall survival compared to those with levels <1300 pg/ml (p< 0.05).
Conclusions: NT-proBNP levels may be able to predict complications and mortality in children with
severe EV71-associated HFMD disease in the intensive care unit. Serum NT-proBNP values1300 pg/ml
on admission could be indicative of circulatory failure and increased mortality.
 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).1. Introduction
Hand, foot, and mouth disease (HFMD) is caused by a variety of
human enteroviruses, mainly by enterovirus 71 (EV71) and
coxsackievirus A16 (CA16), and is characterized by fever and
vesicular exanthema on the hands, feet, andmouth. Themajority of
cases are not life-threatening; however, a small proportion of
HFMD patients do have a poor prognosis, particularly those
infected with EV71.1 Based on the national HFMD surveillance
system in China, the case severity rate of HFMD is 1.1% and the
case-fatality rate is 0.03%.2
Many countries in Asia have experienced an increasing trend of
HFMD outbreaks with deaths among younger children due to
cardiorespiratory dysfunction.3 Such fatal cases are usually found in* Corresponding author. Tel.: +86 13607432330; fax: +86 73185600901.
E-mail address: xiaozhh8888@163.com (Z. Xiao).
1 Jun Qiu and Xiulan Lu contributed equally to this work and should be
considered co-ﬁrst authors.
http://dx.doi.org/10.1016/j.ijid.2016.10.014
1201-9712/ 2016 The Author(s). Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).young infants and are characterized by some serious complications,
such as central nervous system manifestations, pulmonary edema,
pulmonary hemorrhage, circulatory failure, and rapid shock.4
Furthermore, acute heart failure is one of the main manifestations
in severe HFMD patients with circulatory failure. In clinical
practice, acute cardiac dyskinesia, low ejection fraction, and
regional wall motion abnormalities of the left ventricle are often
observed on echocardiography prior to EV71-related death.5,6 The
mortality risk is higher in patientswith severeHFMD complicated
by cardiopulmonary collapse than in patients without cardiopul-
monary collapse. Therefore, acute heart failure has been proposed
as the main indicator of rapid deterioration leading to HFMD-
related mortality.
Brain-type natriuretic peptide (BNP) andN-terminal pro-B-type
natriuretic peptide (NT-proBNP) are released in equimolar
amounts from the myocardium. Their levels increase in response
to hemodynamic stress, and they have an established role in
cardiovascular (vasodilation) and renal (natriuresis) physiology,
conferring protection against ﬂuid overload and hypertension.7ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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the blood in response tomyocardialwall stress caused by excessive
volume or pressure loading of the heart.8 Several studies
performed in the pediatric age group have consistently demon-
strated that blood levels of NT-proBNP are increased in patients
with pulmonary arterial hypertension, Kawasaki disease, and
congestive heart failure.9–11 A recent study demonstrated that a
serum BNP level of >100 pg/ml could be used to detect left
ventricular dysfunction in children with severe EV71 infection.12
Overall, natriuretic peptides, particularly BNP and NT-BNP, predict
poor outcomes in cardiovascular-related diseases. However, our
understanding of the relationships of these peptides to HFMD is
limited and there have been few prospective studies in the general
population.
The purpose of this study was to evaluate whether NT-proBNP
can predict impending brainstem encephalitis, pulmonary edema,
pulmonary hemorrhage, cardiopulmonary failure, and death in
children with severe EV71-associated HFMD.
2. Methods
2.1. Ethics statement
The Ethics Committee of Hunan Children’s Hospital approved
the study (IRB No. HCHLL-2014004). Written informed consent
was obtained from the parents or caretakers of each child included
in this study prior to data collection. All data collected from the
participants were fully anonymized.
2.2. Patients and setting
The study was designed as a prospective cohort study and was
conducted at Hunan Children’s Hospital, which serves a population
of 71 million and a land area of 211 800 km2. The hospital has
1800 beds and 40 of these are in the pediatric intensive care unit
(PICU). Hunan Province is located in Central China, and a
population of 11.574 million children was recorded in 2013.
All of the subjects enrolled in the present study were patients
with HFMD treaded in the PICU between January 2012 and
December 2013. The diagnostic criteria were based on the Chinese
guidelines for the diagnosis and treatment of severeHFMD issued by
the Ministry of Health of China.13 Cases were recorded as having
severe HFMD if they were found to have the more serious
complications including encephalitis, meningitis, acute ﬂaccid
paralysis, and cardiorespiratory failure, or died. Patients who met
the clinical criteria for typical and atypical HFMD were enrolled.
Typical HFMD was deﬁned in the presence of oral and/or peri-oral
erosions and exanthema on the palms of the hands and soles of the
feet;atypicaldiseasewasdeﬁnedasexanthemaatdistinctsitesother
than the oral/peri-oral region, palms of the hands, and soles of the
feet.
Typical and atypical HFMD patients were diagnosed based on
their clinical presentation and the detection of EV71 by two
attending doctorswith 5 years of experience in the PICU. The EV71-
associated HFMD patients were divided into four subgroups based
on the clinical staging of their disease during the course of
hospitalization: stage I (onset: herpangina and fever), stage II
(encephalitis: myoclonic jerking with vomiting, upward gaze,
seizure, or ataxia), stage III (with complications of encephalitis plus
tachycardia, hyperglycemia, tachypnea, or hypertension), stage IV
(with complications of cardiopulmonary failure: hypoxia, hypo-
tension, shock, pulmonary edema, or hemorrhage).14 Hypertension
was deﬁned according to the age-speciﬁc limits in the fourth report
on the diagnosis, evaluation, and treatment of high blood pressure
in children and adolescents.15 All of the stage II patients were
admitted to the PICU.Patients were excluded if their clinical presentation could be
explained by another speciﬁc illness, such as varicella, herpes
simplex virus, herpes zoster, contact dermatitis, atopic dermatitis,
bullous impetigo, or other bullous diseases. Patients with
incomplete medical records were also excluded. Ultimately,
282 patients with EV71-associated HFMD were enrolled in the
study. The following patient data were obtained from the medical
records: age, sex, diagnosis, temperature, respiratory rate, heart
rate, blood pressure, oxygen saturation, white blood cell (WBC)
count, platelet count, blood glucose level, and arterial blood gas
results.
2.3. Serum NT-proBNP analysis
A venous blood sample (4 ml) for the detection of NT-proBNP
was collected during the ﬁrst hour of hospital admission and was
stored immediately at 70 8C. The samples were centrifuged at
3000 rpm for 20 min and analyzed using an electrochemilumines-
cence immunoassay (Elecsys NT-proBNP; bioMe´rieux, Lyons,
France). The clinical caregivers were blinded to the NT-proBNP
values in order to avoid changes to the clinical interventions based
on the results. The red blood cell count (RBC), hemoglobin level
(Hb), WBC count, and neutrophil count (Neu) were determined
using a Sysmex XE-2100 Automated Hematological Parameters
Analyzer (Sysmex, Japan).
2.4. Statistical analysis
SPSS version 18.0 software (SPSS Inc., Chicago, IL, USA)was used
for the data analysis. The NT-proBNP level was log-transformed
because it was non-normally distributed. Continuous data were
described using the mean and standard deviation. The Student
t-test and one-way analysis of variance were used to compare the
NT-proBNP values among the groups. The Spearman coefﬁcient
was used to assess the correlation between quantitative variables.
The receiver operating characteristic (ROC) curve was drawn for
NT-proBNP to distinguish between survival and non-survival
among the patients with HFMD. The area under the ROC curve
(AUC), 95% conﬁdence interval (CI), sensitivity, speciﬁcity, positive
predictive value (PPV), and negative predictive value (NPV) were
analyzed to determine the optimal cut-off values of NT-proBNP for
the diagnosis of complications or death in severe cases of HFMD.
The diagnostic predictive value was deemed signiﬁcant when the
AUC was > 0.70. The survival rate was calculated using the
Kaplan–Meiermethod and differences between the survival curves
were tested for statistical signiﬁcance using the log-rank test. For
all of the tests, p < 0.05 was considered statistically signiﬁcant.
3. Results
3.1. Baseline clinical and laboratory characteristics
A total of 282 patients with EV71-associated HFMD were
recruited into the study; 183 (64.89%) were male and the median
age of the cohortwas 21months (interquartile range (IQR) 15.75–31
months). In total, 282 HFMD cases were caused by EV71; their
mortality rate from EV71 was 7.09% (20/282). Table 1 shows the
baseline demographic and clinical characteristics of the patients
with HFMD.
The median NT-proBNP level was 184.50 pg/ml (IQR 53.25–
528.25 pg/ml). The mean (standard deviation) log10 NT-proBNP
level was 2.31 (0.75). The log10 NT-proBNP level differed
signiﬁcantly among the subgroups of patients according to age,
blood pressure, and heart rate (p < 0.05). The NT-proBNP levels
were signiﬁcantly higher in patients with increased blood glucose
levels (>7.8 mmol/l; p < 0.001), and the correlation among them
Table 1
Baseline clinical and laboratory characteristics of the 282 patients with EV71
Clinical features n (%) Log10 NT-proBNP t/F p-Value
Age group
5 years 274 (97.16) 2.32 0.74 1.55 0.12
>5 years 8 (2.84) 1.91 0.86
Sex
Male 183 (64.89) 2.32 0.67 0.24 0.81
Female 99 (35.11) 2.30 0.87
Blood pressure
Hypertension (greater than age-deﬁned limit) 32 (11.35) 2.51 0.91 1.34 0.19
No hypertension 250 (88.65) 2.29 0.72
Heart rate
170/min 30 (10.64) 3.031.03 4.21 <0.0001
<170/min 252 (89.36) 2.22 0.66
Blood glucose
>7.8 mmol/l 47 (16.67) 2.82 0.94 4.25 <0.0001
7.8 mmol/l 235 (83.33) 2.21 0.66
White blood cell count
>14109/l 58 (20.57) 2.72 0.89 4.14 <0.0001
14109/l 224 (79.43) 2.20 0.66
EV71 patient stage
Stage II 242 (85.82) 2.15 0.57 65.79 <0.0001
Stage III 12 (4.26) 2.801.05
Stage IV 28 (9.92) 3.52 0.77
EV71, enterovirus 71; NT-proBNP, N-terminal pro-B-type natriuretic peptide.
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signiﬁcantly higher in patients with an increased WBC count
(>14  109/l, p < 0.001), and the correlation among them was
signiﬁcant (r = 0.142, p = 0.017). In the 282 EV71-associated HFMD
patients, the log10 NT-proBNP level was the highest in stage IV, and
the difference was statistically signiﬁcant (F = 65.79, p < 0.0001).
3.2. Level of NT-proBNP at different clinical stages
The patients with HFMD were divided into three subgroups
based on the clinical staging of their disease severity: 242 cases
(85.82%) had stage II disease, 12 cases (4.26%) had stage III, and
28 cases (9.92%) had stage IV. The log10 NT-proBNP levels in the
different subgroups are shown in Figure 1. Stage II patients had the
lowest log10 NT-proBNP level and stage IV patients had the highest
[(Figure_1)TD$FIG]Figure 1. N-terminal pro-B-type natriuretic peptide (NT-proBNP) values in the
different subgroups of patients with enterovirus 71 (EV71)-associated hand, foot,
and mouth disease (HFMD). The median NT-proBNP level was 136.50 pg/ml (IQR
47.75–356.50 pg/ml) in stage II, 539.50 pg/ml (IQR 139.72–12 332.72 pg/ml) in
stage III, and 5331.00 pg/ml (IQR 1422.00–12 092.00 pg/ml) in stage IV. The NT-
proBNP level in stage IV HFMD patients was signiﬁcantly higher than that in the
other HFMD patients (F = 65.79, p < 0.0001).log10 NT-proBNP level, and the difference between the groups was
statistically signiﬁcant according to single factor analysis of
variance (F = 65.79, p < 0.0001).
3.3. NT-proBNP values for different complications and death
In this study, 61 (21.63%) cases were complicated with
brainstem encephalitis, 37 (13.12%) with pulmonary edema,
28 (9.93%) with pulmonary hemorrhage, and 26 (9.22%) with
circulatory failure during the period of hospitalization. Of the
282 patients with EV71-associated HFMD, 20 (7.09%) died while in
the hospital. The median NT-proBNP was 641.00 (IQR 118.00–
6358.50) pg/ml in the patients with brainstem encephalitis, 5061.00
(IQR 539.50–11 726.00) pg/ml in the patients with pulmonary
edema, 5331.00 (IQR 1422.00–12 092.00) pg/ml in the patients with
pulmonary hemorrhage, 5621.00 (IQR 2190.00–13 548.50) pg/ml in
patients with circulatory failure, and 6284.00 (IQR 1852–17 813.00)
pg/ml in the 20 patients who died. As shown in Table 2, the mean
log10 NT-proBNP levels differed signiﬁcantly between the severe
HFMD patients with andwithout complications, and themean log10
NT-proBNP value in the patients who died was signiﬁcantly higher
than the value in the patients who survived (p< 0.05).Table 2
Different log10 NT-proBNP levels according to the different complications and
prognosis
Complications n (%) Log10 NT-proBNP t p-Value
Brainstem encephalitis
Yes 61 (21.63) 2.920.99 5.87 0.001
No 221 (78.37) 2.140.56
Pulmonary edema
Yes 37 (13.12) 3.360.85 8.38 0.001
No 245 (86.88) 2.150.59
Pulmonary hemorrhage
Yes 28 (9.93) 3.520.77 10.68 0.001
No 254 (90.07) 2.180.61
Circulatory failure
Yes 26 (9.22) 3.630.67 11.45 0.001
No 256 (90.78) 2.180.61
Death
Yes 20 (7.09) 3.660.72 9.64 0.001
No 262 (92.91) 2.210.64
NT-proBNP, N-terminal pro-B-type natriuretic peptide.
[(Figure_2)TD$FIG]
Figure 2. Comparison of the receiver operating characteristic (ROC) curves of white blood cell (WBC) count, blood glucose, and N-terminal pro-B-type natriuretic peptide
(NT-proBNP) to discriminate between patients with and without brainstem encephalitis. The area under the curve (AUC) was 0.66 (95% CI 0.58–0.75), 0.70 (95% CI 0.62–0.78),
and 0.73 (95% CI 0.65–0.82) to discriminate between patients with and without brainstem encephalitis by WBC count, glucose level, and NT-proBNP level, respectively.
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or death by WBC count, blood glucose, and NT-proBNP
Figures 2–6 show the discrimination between the HFMD
patients with and without complications or death. The AUC was
[(Figure_3)TD$FIG]Figure 3. Comparison of the receiver operating characteristic (ROC) curves of white blo
(NT-proBNP) to discriminate between patients with andwithout pulmonary edema. The
0.87 (95% CI 0.80–0.95) to discriminate between patients with and without pulmonary0.66 (95% CI 0.58–0.75), 0.70 (95% CI 0.62–0.78), and 0.73 (95% CI
0.65–0.82) to discriminate between patients with and without
brainstem encephalitis byWBC count, blood glucose level, and NT-
proBNP level, respectively (Figure 2). The AUC was 0.76 (95% CI
0.66–0.86), 0.81 (95% CI 0.73–0.90), and 0.87 (95% CI 0.80–0.95) tood cell (WBC) count, blood glucose, and N-terminal pro-B-type natriuretic peptide
area under the curve (AUC)was 0.76 (95% CI 0.66–0.86), 0.81 (95% CI 0.73–0.90), and
edema by WBC count, glucose level, and NT-proBNP level, respectively.
[(Figure_4)TD$FIG]
Figure 4. Comparison of the receiver operating characteristic (ROC) curves of white blood cell (WBC) count, blood glucose, and N-terminal pro-B-type natriuretic peptide
(NT-proBNP) to discriminate between patients with and without pulmonary hemorrhage. The area under the curve (AUC) was 0.81 (95% CI 0.71–0.91), 0.84 (95% CI 0.74–0.94),
and 0.91 (95% CI 0.84–0.98) to discriminate between patients with and without pulmonary hemorrhage by WBC count, glucose level, and NT-proBNP level, respectively.
[(Figure_5)TD$FIG]
Figure 5. Comparison of the receiver operating characteristic (ROC) curves of white blood cell (WBC) count, blood glucose, and N-terminal pro-B-type natriuretic peptide
(NT-proBNP) to discriminate between patients with and without circulatory failure. The area under the curve (AUC) was 0.84 (95% CI 0.76–0.92), 0.84 (95% CI 0.74–0.94), and
0.93 (95% CI 0.87–0.99) to discriminate between patients with and without circulatory failure by WBC count, glucose level, and NT-proBNP level, respectively.
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edema by WBC count, blood glucose level, and NT-proBNP level,
respectively (Figure 3). The AUC was 0.81 (95% CI 0.71–0.91),
0.84 (95% CI 0.74–0.94), and 0.91 (95% CI 0.84–0.98) to
discriminate between patients with and without pulmonary
hemorrhage by WBC count, blood glucose level, and NT-proBNPlevel, respectively (Figure 4). The AUCwas 0.84 (95% CI 0.76–0.92),
0.84 (95% CI 0.74–0.94), and 0.93 (95% CI 0.87–0.99) to
discriminate between patients with and without circulatory
failure by WBC count, blood glucose level, and NT-proBNP
level, respectively (Figure 5). The AUC was 0.84 (95% CI
0.74–0.93) and 0.86 (95% CI 0.76–0.96) to discriminate between
[(Figure_6)TD$FIG]
Figure 6. Comparison of the receiver operating characteristic (ROC) curves of white blood cell (WBC) count, blood glucose, and N-terminal pro-B-type natriuretic peptide
(NT-proBNP) to discriminate between patients who did and did not die. The area under the curve (AUC) was 0.84 (95% CI 0.74–0.93), 0.86 (95% CI 0.76–0.96), and 0.92
(95% CI 0.84–0.99) to discriminate between patients who did and did not die by WBC count, glucose level, and NT-proBNP level, respectively.
J. Qiu et al. / International Journal of Infectious Diseases 54 (2017) 64–71 69patients with and without death by WBC count and blood
glucose level, respectively. The AUC was 0.92 (95% CI 0.84–0.99)
to discriminate between patients who died and those who
survived by NT-proBNP level, and the ‘optimal’ cut-off point for
NT-proBNP was 1300 pg/ml based on the maximum Youden
index (Figure 6).
In all cases with poor outcomes, the NT-proBNP level was
observed to have a better area under the ROC curve than either
WBC count or blood glucose. At the ‘optimal’ cut-off point of
[(Figure_7)TD$FIG]Figure 7. Unadjusted Kaplan–Meier survival curves for patients with hand, foot, and
(NT-proBNP) concentration. The Kaplan–Meier survival curves for HFMD patients were
NT-proBNP 1300 pg/ml. Patients with NT-proBNP levels above 1300 pg/ml had signiﬁ1300 pg/ml, the sensitivity of the NT-proBNP level for patientswho
died was 85.00%, the speciﬁcity was 93.51%, the PPV was 50.00%,
and the NPV was 98.79%.
3.5. Survival curves by NT-proBNP level
ROC curve analysis showed that the NT-proBNP value with the
highest sensitivity and speciﬁcity for death was 1300 pg/ml.
PatientswithNT-proBNP levels above 1300 pg/ml had signiﬁcantlymouth disease (HFMD) stratiﬁed by N-terminal pro-B-type natriuretic peptide
stratiﬁed into two different categories of NT-proBNP: NT-proBNP <1300 pg/ml and
cantly worse overall survival.
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associated HFMD patients died, as compared to three out of the
248 EV71-associated HFMD patients with NT-proBNP concentra-
tions below 1300 pg/ml at 30 days (log rank p = 0.001).
4. Discussion
NT-proBNP is a valuable biomarker in clinical practice in
patients with heart failure and ventricular overload, because it can
bemeasured rapidly and accurately at a reasonable cost and can be
used to help guide patient management.16 Recent studies have
demonstrated that the BNP or NT-proBNP levels may be useful for
distinguishing acute heart failure and ventricular overload in
adults with heart failure, systolic and diastolic dysfunction, and
other types of hemodynamic overload of the heart.17,18 However,
the clinical application of NT-proBNP in HFMD patients with or
without acute heart failure remains limited. This study demon-
strated that the NT-proBNP levels were signiﬁcantly increased in
EV71-associated HFMD patients with disease stages III or IV,
increased blood glucose levels, or increased WBC counts. The NT-
proBNP level was a better biomarker than either leukocytosis or
hyperglycemia to discriminate severe EV71-associated HFMD
patients with or without severe complications. In this study, the
log10 NT-proBNP levels differed signiﬁcantly between severe
EV71-associated HFMD patients with and without complications
or death. It was also demonstrated that the NT-proBNP levels
predicted different complications or death in EV71-associated
HFMD patients. It was clearly demonstrated that NT-proBNP levels
above 1300 pg/ml on admission showed a signiﬁcant association
with all-cause mortality. Thus, serum NT-proBNP was a good
marker to predict impending pulmonary edema, pulmonary
hemorrhage, circulatory failure, or death and could allow for the
timely initiation of appropriate interventions to reduce mortality
in patients with severe EV71-associated HFMD.
In the present study, it was found that the NT-proBNP levels
were signiﬁcantly higher in patients with increasedWBC counts or
raised glucose levels, and NT-proBNP was positively correlated
with WBC counts and blood glucose levels. Several studies have
shown that hyperglycemia and leukocytosis are associated with
fatal EV71 disease.19,20 In a recent publication, Song et al.
demonstrated that vomiting, circulatory disturbance, EV71 infec-
tion, dysfunction of respiratory rhythm, and high BNP levels were
ﬁve independent risk factors for severe HFMD complicated with
cardiopulmonary collapse.21 Similarly, Lee et al. reported that
patients with an admission NT-proBNP level of over 1500 pg/dl
were 22.5 timesmore likely to die within 3 days of admission, after
adjusting for clinical predictors.22 Thus, like the WBC count or
blood glucose level, the NT-proBNP level may reﬂect the severity of
disease in patients with HFMD.
Furthermore, the present study demonstrated that the AUC of
NT-proBNPwas higher than that of theWBC count or blood glucose
for discriminating severe HFMD patients with or without severe
complications.While, previous studies have demonstrated that the
leukocyte count and serum glucose can predict the severity of
HFMD, these are late symptoms that generally occur with
fulminant disease and have the problem of being non-speciﬁc
and correlate poorly with neurological complications.23,24 Thus,
NT-proBNP will be a better biomarker than the WBC count or
hyperglycemia to discriminate severe HFMD patients with or
without severe complications.
This research demonstrated that the serum NT-proBNP level
was markedly increased in severe EV71-associated HFMD cases
complicated by pulmonary edema, pulmonary hemorrhage, heart
failure, and even death, and was signiﬁcantly increased in stage III
and IV EV71-associated HFMD patients. In China, some studies
have demonstrated that NT-proBNP and BNP levels in HFMDpatients with different stages or different complications are
different, which may reﬂect the changes in heart function in the
different stages of HFMD in children.25,26 Patients with severe
HFMD may progress to acute heart failure, but symptoms of heart
failure are insensitive for diagnosing heart failure.5,14 NT-proBNP is
an indicator that is more stable and precise to reﬂect the
cardiovascular status of the patient than BNP, and is helpful for
diagnosing patients with suspected myocardial stress who have
new symptoms of heart failure or acute respiratory distress, and for
assessing the prognosis of heart failure in patients.27
A recent study demonstrated that the BNP level may be used to
aid in the diagnosis of children who have severe EV71 infections
with varying degrees of acute myocardial stress, and a BNP cut-off
value of 100 pg/mlwas used to detect severe EV71with acute heart
failure.12 In patients with HFMD complicated by brainstem
encephalitis, the overexcited sympathetic nervous system could
release abundant catecholamines and increase myocardial
stress.28 In turn, the myocardial stress could induce neurogenic
pulmonary edema, pulmonary hemorrhage, and heart failure,
which are the main causes of death in severe HFMD.1,29 BNP and
NT-proBNP are released from the heart into the bloodstream in
response to increased ventricular volume or pressure resulting in
myocardial dysfunction.30,31 Thus, the NT-proBNP level is signiﬁ-
cantly higher in patients with acute heart failure because the
pressure loading on their myocardium increases suddenly and the
myocardium cannot tolerate the high wall tension and stress. The
serum NT-proBNP level can reﬂect the cardiovascular status of
early severe EV71-associated HFMD, and may help clinicians
indentify patients with a worse prognosis before they develop
pulmonary edema, pulmonary hemorrhage, or heart failure.
It was also demonstrated in this study that NT-proBNP levels
could predict different complications or death in EV71-associated
HFMD patients, and that an NT-proBNP level above 1300 pg/ml
had a sensitivity of 85.00% and a speciﬁcity of 93.51% for predicting
death in these patients. In China, another study reported that NT-
proBNP500 pg/mlwas the optimal cut-off value for the diagnosis
of heart failure in children.32 Kocharian et al. demonstrated that
the optimal cut-off values of plasma NT-proBNP for the diagnosis
of systolic or diastolic dysfunction were 336.5 pg/ml and 178 pg/
ml, respectively, in children with cardiac disease.33 Lu et al. found
that an NT-proBNP above 950 ng/l had 88.10% sensitivity and
89.00% speciﬁcity for the diagnosis of coronary arterial lesions, and
that plasma NT-proBNP could be used to predict the risk of
coronary arterial lesions in acute Kawasaki disease.34
NT-proBNP is synthesized and secreted by ventricular myo-
cytes, and an increased cardiac volume or pressure load induces
the synthesis of NT-proBNP.30 Previous studies have reported that
NT-proBNP levels are increased in cardiopulmonary collapse, and
they are widely used in the diagnosis of cardiopulmonary collapse
and the prognosis of angiocardiopathy.11,35 These ﬁndings are
consistent with the results of the present study showing that
patients with severe EV71-associated HFMD with cardiopulmo-
nary collapse had signiﬁcantly increased NT-proBNP levels.
Therefore, clinicians should be alert to the risk of cardiopulmonary
failure in children with EV71-associated HFMD complicated by
increased NT-proBNP levels.
In this study, it was clearly demonstrated that NT-proBNP levels
above 1300 pg/ml on admission showed a signiﬁcant association
with all-cause mortality. NT-proBNP levels increased as the
severity of HFMD increased. Children with NT-proBNP
1300 pg/ml were more likely to develop pulmonary edema,
pulmonary hemorrhage, and heart failure, and even die. In brief, a
serum NT-proBNP level above 1300 pg/ml on admission should
alert clinicians to take action to protect a child from cardiovascular
complications such as pulmonary edema and heart failure. Thus,
serum NT-proBNP appears to be a good marker to predict
J. Qiu et al. / International Journal of Infectious Diseases 54 (2017) 64–71 71impending pulmonary edema, pulmonary hemorrhage, circulatory
failure, and death, and clinicians could use this marker to
implement appropriate interventions to reducemortality in severe
EV71-associated HFMD cases.
This study has some limitations. First, it was a small, single-
center, prospective cohort study and had the inherent limitations
that are common to all observational studies. Second, no
echocardiography examinations were performed on the severe
HFMD cases, because even in wealthier Asian countries, such
testing is not included in routine clinical practice because of poor
availability of the technologically advanced equipment. Third, the
NT-proBNP levels were not dynamically monitored for the severe
HFMD patients in this study. Finally, patients with other infectious
diseases admitted to the PICU were not recruited into a control
group for this study.
In conclusion, as with the WBC count and blood glucose level,
the NT-proBNP level can reﬂect the severity of EV71-associated
HFMD, and NT-proBNP appears to be a better biomarker than the
WBC count or hyperglycemia to discriminate severe HFMD
patients with or without severe complications. NT-proBNP levels
may be able to predict complications or mortality in children with
severe EV71-associated HFMD disease in the intensive care unit.
An NT-proBNP cut-off value of 1300 pg/ml demonstrated a high
sensitivity and speciﬁcity for predicting death in patients with
severe EV71-associated HFMD. Serum values of NT-proBNP
1300 pg/ml on admission should alert clinicians to the potential
for circulatory failure and an increased mortality risk.
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